Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDK | P21741 | 4/20 | 0.53 |
| ▸ | SERPINC1 | P01008 | 3/20 | 0.49 |
| ▸ | FGF1 | P05230 | 1/20 | 0.48 |
| ▸ | FGF2 | P09038 | 1/20 | 0.48 |
| ▸ | VEGFA | P15692 | 1/20 | 0.48 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12606419 | 0.91 | MDK (0.49) | MDKSERPINC1FGF1FGF2VEGFA | |
| SCHEMBL12606413 | 0.91 | MDK (0.49) | MDKSERPINC1FGF1FGF2VEGFA | |
| SCHEMBL13039111 | 0.88 | MDK (0.49) | MDKSERPINC1FGF1FGF2VEGFA | |
| SCHEMBL13039112 | 0.88 | MDK (0.49) | MDKSERPINC1FGF1FGF2VEGFA | |
| SCHEMBL14363910 | 0.88 | MDK (0.49) | MDKSERPINC1FGF1FGF2VEGFA | |
| SCHEMBL14363913 | 0.88 | MDK (0.49) | MDKSERPINC1FGF1FGF2VEGFA | |
| SCHEMBL12606415 | 0.87 | MDK (0.46) | MDKSERPINC1FGF1FGF2VEGFA | |
| SCHEMBL12458589 | 0.83 | MDK (0.51) | MDKSERPINC1FGF1FGF2VEGFA | |
| SCHEMBL13551197 | 0.81 | MDK (0.49) | MDKSERPINC1CAPN1F2PRSS1 | |
| SCHEMBL12799305 | 0.81 | MDK (0.49) | MDKSERPINC1FGF1FGF2VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066065-A1 | PLATELET DERIVATIVES FOR TREATING COAGULOPATHY | CELLPHIRE, INC. (US) | 2024-02-29 | — | — | US | claimed |
| US-11524978-B2 | Synthetic peptides, pharmaceutical compositions comprising the same, and uses thereof in treating thromboembolism-related diseases | ACADEMIA SINICA (TW) | 2022-12-13 | — | — | US | claimed |
| US-20220380478-A1 | ANTI-CD154 ANTIBODIES AND USES THEREOF | TONIX PHARMACEUTICALS HOLDING CORP. | 2022-12-01 | — | — | US | claimed |
| US-20220279777-A1 | FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTICOAGULANT-INDUCED COAGULOPATHY | CELLPHIRE INC. (US) | 2022-09-08 | — | — | US | claimed |
| WO-2022178191-A1 | FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTICOAGULANT-INDUCED COAGULOPATHY | CELLPHIRE, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| EP-4013432-A1 | THROMBOSOMES AS AN ANTICOAGULANT REVERSAL AGENT | Cellphire Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| EP-3993876-A1 | ANTI-CD154 ANTIBODIES AND USES THEREOF | Tonix Pharma Limited (IE) | 2022-05-11 | — | — | EP | claimed |
| US-11318331-B2 | Pulmonary hypertension treatment | SONIVIE LTD. (IL) | 2022-05-03 | — | — | US | claimed |
| CN-114423785-A | anti-CD 154 antibodies and uses thereof | 通尼克斯制药有限公司 | 2022-04-29 | — | — | CN | claimed |
| EP-4747379-A1 | AGENTS FOR TREATING CANCER | Toumpoulis, Ioannis (GR) | 2026-05-27 | — | — | EP | disclosed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-20260115271-A1 | MULTIVALENT PNEUMOCOCCAL VACCINES | AFFINIVAX, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4728275-A1 | METHODS AND ASSAYS FOR IMMUNE PHENOTYPING | Immune Functional Diagnostics, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12605341-B2 | Dry powder composition for peroral administration | VICORE PHARMA AB (SE) | 2026-04-21 | — | — | US | disclosed |
| EP-3980400-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | Emory University (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-114269296-A | Methods and devices for treating iliac cavity compression, occlusion, vein caliber reduction, and occlusion-induced syndromes and conditions | DP控股(英国)有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3965700-A1 | METHODS AND DEVICES FOR TREATING ILIOCAVAL COMPRESSION, OCCLUSION, REDUCTION OF VENOUS CALIBER, AND SYNDROMES AND DISEASE STATES RESULTING FROM OCCLUSION | DP Holding (U.K) Ltd. (GB) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022049372-A1 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | VICORE PHARMA AB (SE) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022051606-A1 | NITRIC OXIDE DONORS, COMPOSITIONS, AND METHODS OF USE | KNOW BIO, LLC (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220047586-A1 | COMPOSITION AND METHODS FOR PREVENTING OR REDUCING THE INCIDENCE OF TRANSIENT ISCHEMIC ATTACKS | MOREHOUSE SCHOOL OF MEDICINE | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605341-B2 | Dry powder composition for peroral administration | GYS1, GYS2, SI | MDK 3103/4885SERPINC1 3764/4885FGF1 1419/4885 |
| US-20260115271-A1 | MULTIVALENT PNEUMOCOCCAL VACCINES | SPPL2B, SPAG5, SPPL2A | MDK 3080/4885SERPINC1 1072/4885FGF1 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.